Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFIRT: Reduced-field RT + Sintilimab in Rectal Cancer
NCT07161115Phase 2Not yet recruiting
- Start
- Sep 2025
- Primary completion
- Aug 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab in rectal adenocarcinoma (3 arms). Primary endpoint: Two-year local control rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT07161115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07161115.